vs
Orthofix Medical Inc.（OFIX）与VIRTUS INVESTMENT PARTNERS, INC.（VRTS）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是VIRTUS INVESTMENT PARTNERS, INC.的1.1倍（$219.9M vs $199.5M），VIRTUS INVESTMENT PARTNERS, INC.净利率更高（3.6% vs -1.0%，领先4.6%），Orthofix Medical Inc.同比增速更快（2.0% vs -4.1%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -5.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Virtus Investment Partners是一家美国多管理人资产管理企业，旗下汇集多家具备独立投资流程与自有品牌的关联投资管理人，同时也提供非关联子投资顾问服务，为客户提供多元化的资产管理解决方案。
OFIX vs VRTS — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$199.5M
营收增速更快
OFIX
高出6.1%
-4.1%
净利率更高
VRTS
高出4.6%
-1.0%
两年增速更快
OFIX
近两年复合增速
-5.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $199.5M |
| 净利润 | $-2.2M | $7.1M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 7.7% |
| 净利率 | -1.0% | 3.6% |
| 营收同比 | 2.0% | -4.1% |
| 净利润同比 | 92.4% | -78.1% |
| 每股收益（稀释后） | $-0.05 | $1.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXVRTS
| Q1 26 | — | $199.5M | ||
| Q4 25 | $219.9M | $208.0M | ||
| Q3 25 | $205.6M | $216.4M | ||
| Q2 25 | $203.1M | $210.5M | ||
| Q1 25 | $193.6M | $217.9M | ||
| Q4 24 | $215.7M | $233.5M | ||
| Q3 24 | $196.6M | $227.0M | ||
| Q2 24 | $198.6M | $224.4M |
净利润OFIXVRTS
| Q1 26 | — | $7.1M | ||
| Q4 25 | $-2.2M | $33.9M | ||
| Q3 25 | $-22.8M | $31.3M | ||
| Q2 25 | $-14.1M | $42.7M | ||
| Q1 25 | $-53.1M | $28.1M | ||
| Q4 24 | $-29.1M | $39.5M | ||
| Q3 24 | $-27.4M | $49.1M | ||
| Q2 24 | $-33.4M | $26.0M |
毛利率OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXVRTS
| Q1 26 | — | 7.7% | ||
| Q4 25 | 0.2% | 19.1% | ||
| Q3 25 | -8.3% | 21.7% | ||
| Q2 25 | -7.9% | 21.5% | ||
| Q1 25 | -25.2% | 16.8% | ||
| Q4 24 | -5.3% | 21.7% | ||
| Q3 24 | -9.6% | 24.3% | ||
| Q2 24 | -12.5% | 19.7% |
净利率OFIXVRTS
| Q1 26 | — | 3.6% | ||
| Q4 25 | -1.0% | 16.3% | ||
| Q3 25 | -11.1% | 14.5% | ||
| Q2 25 | -6.9% | 20.3% | ||
| Q1 25 | -27.4% | 12.9% | ||
| Q4 24 | -13.5% | 16.9% | ||
| Q3 24 | -13.9% | 21.6% | ||
| Q2 24 | -16.8% | 11.6% |
每股收益（稀释后）OFIXVRTS
| Q1 26 | — | $1.05 | ||
| Q4 25 | $-0.05 | $5.15 | ||
| Q3 25 | $-0.57 | $4.65 | ||
| Q2 25 | $-0.36 | $6.12 | ||
| Q1 25 | $-1.35 | $4.05 | ||
| Q4 24 | $-0.76 | $4.65 | ||
| Q3 24 | $-0.71 | $5.71 | ||
| Q2 24 | $-0.88 | $2.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $136.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $93.6B |
| 总资产 | $850.6M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXVRTS
| Q1 26 | — | $136.6M | ||
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — |
总债务OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | — | $390.0M | ||
| Q3 25 | $157.2M | $390.6M | ||
| Q2 25 | $157.0M | $231.3M | ||
| Q1 25 | $156.9M | $231.7M | ||
| Q4 24 | $157.0M | $232.1M | ||
| Q3 24 | $118.5M | $237.5M | ||
| Q2 24 | $118.0M | $247.6M |
股东权益OFIXVRTS
| Q1 26 | — | $93.6B | ||
| Q4 25 | $450.0M | $934.0M | ||
| Q3 25 | $442.5M | $918.7M | ||
| Q2 25 | $458.3M | $896.4M | ||
| Q1 25 | $458.3M | $893.7M | ||
| Q4 24 | $503.1M | $897.5M | ||
| Q3 24 | $525.9M | $889.0M | ||
| Q2 24 | $546.0M | $868.7M |
总资产OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | $850.6M | $4.3B | ||
| Q3 25 | $832.6M | $3.9B | ||
| Q2 25 | $837.2M | $3.7B | ||
| Q1 25 | $823.1M | $3.7B | ||
| Q4 24 | $893.3M | $4.0B | ||
| Q3 24 | $867.9M | $3.6B | ||
| Q2 24 | $882.0M | $3.6B |
负债/权益比OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.42× | ||
| Q3 25 | 0.36× | 0.43× | ||
| Q2 25 | 0.34× | 0.26× | ||
| Q1 25 | 0.34× | 0.26× | ||
| Q4 24 | 0.31× | 0.26× | ||
| Q3 24 | 0.23× | 0.27× | ||
| Q2 24 | 0.22× | 0.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $-67.2M | ||
| Q3 25 | $12.4M | $108.3M | ||
| Q2 25 | $11.6M | $75.8M | ||
| Q1 25 | $-18.4M | $-3.8M | ||
| Q4 24 | $23.7M | $1.8M | ||
| Q3 24 | $11.7M | $69.1M | ||
| Q2 24 | $9.0M | $70.0M |
自由现金流OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $-74.1M | ||
| Q3 25 | $2.5M | $106.9M | ||
| Q2 25 | $4.5M | $74.2M | ||
| Q1 25 | $-25.1M | $-6.8M | ||
| Q4 24 | $15.2M | $-3.8M | ||
| Q3 24 | $6.3M | $68.7M | ||
| Q2 24 | $-360.0K | $68.6M |
自由现金流率OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | -35.6% | ||
| Q3 25 | 1.2% | 49.4% | ||
| Q2 25 | 2.2% | 35.2% | ||
| Q1 25 | -13.0% | -3.1% | ||
| Q4 24 | 7.0% | -1.6% | ||
| Q3 24 | 3.2% | 30.3% | ||
| Q2 24 | -0.2% | 30.6% |
资本支出强度OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 3.3% | ||
| Q3 25 | 4.8% | 0.7% | ||
| Q2 25 | 3.5% | 0.7% | ||
| Q1 25 | 3.5% | 1.4% | ||
| Q4 24 | 4.0% | 2.4% | ||
| Q3 24 | 2.7% | 0.2% | ||
| Q2 24 | 4.7% | 0.6% |
现金转化率OFIXVRTS
| Q1 26 | — | — | ||
| Q4 25 | — | -1.99× | ||
| Q3 25 | — | 3.45× | ||
| Q2 25 | — | 1.77× | ||
| Q1 25 | — | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 2.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
VRTS
| Investment management fees | $169.1M | 85% |
| Administration and shareholder service fees | $17.3M | 9% |
| Distribution and service fees | $11.6M | 6% |
